InnoCare Pharma Begins Dosing for Stage III Cancer Patients

InnoCare Pharma, a leading biopharmaceutical company focused on the treatment of cancer and autoimmune diseases, announced that the first patient received a dose of the company's BTK (Bruton tyrosine kinase) inhibitor, orelabrutinib, in a phase III registry study for primary immune thrombocytopenia (ITP ). In China. According to data presented at the Hybrid Congress of the European Hematology Association (EHA) 2023 (abstract number: S299), results of a phase II study showed that both orelabrutinib 50 mg QD and 30 mg QD were safe in the treatment of patients with ITP , with 40 percent of patients in the 50 mg group responding to the primary endpoint. The new BTK inhibitor orelabrutinib developed by InnoCare has high target selectivity and a good safety profile, which makes it suitable for various autoimmune diseases .

There are currently no BTK inhibitors approved worldwide for the treatment of ITP. Dr Jasmine Cui, Co-Founder, President and CEO of InnoCare, said: “BTK inhibitors such as orelabrutinib hold the promise of revolutionizing the treatment of ITP by significantly reducing platelet destruction and the production of pathogenic autoantibodies. Orelabrutinib has consistently shown promising efficacy and safety in the treatment of autoimmune diseases, including ITP. We are committed to accelerating its clinical development to provide the earliest possible new treatment options for patients battling autoimmune diseases such as ITP. ITP is an acquired immune-mediated disease characterized by a decrease in the number of platelets in the peripheral blood, which increases the risk of bruising and bleeding. The annual incidence of ITP in adults is approximately 2-10 cases per 100,000 people. Only about 70% of patients respond to first-line treatment. Therefore, it is necessary to look for new forms of treatment. Orelabrutinib is expected to be a better treatment option for patients with ITP. Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.